Netupitant/palonosetron
Combination of | |
---|---|
Netupitant | NK1 receptor antagonist |
Palonosetron | 5-HT3 receptor antagonist |
Names | |
Trade names | Akynzeo |
Clinical data | |
Main uses | Chemotherapy-induced nausea and vomiting[1] |
Side effects | Headache, constipation, tiredness[2] |
Pregnancy category | |
Routes of use | By mouth, intravenous |
External links | |
AHFS/Drugs.com | Monograph |
MedlinePlus | a614053 |
Legal | |
License data | |
Legal status |
Netupitant/palonosetron, sold under the brand name Akynzeo, is a combination medication for prevention of acute and delayed chemotherapy-induced nausea and vomiting.[1] It is taken by mouth.[1] It is used with dexamethasone.[1]
Common side effects include headache, constipation, and tiredness.[2] The dose does not need to be adjusted in those with mild to moderate liver or kidney problems.[1] Use is not recommended in pregnancy.[7] Netupitant is an NK1 receptor blocker and palonosetron is a 5-HT3 receptor blocker.[2]
The combination was approved for medical use in the United States in 2014 and Europe in 2015.[1][2] In the United Kingdom it costs the NHS about £70 a dose as of 2021.[7] In the United States this amount costs about 680 USD.[8]
Medical use
Dosage
The typical dose is one capsule a hour before chemotherapy.[2] This contains 300 mg of netupitant and 0.5 mg of palonosetron.[1]
There is an intravenous version that contains fosnetupitant and palonosetron.[9][6]
Contraindications
Netupitant/palonosetron may be contraindicated during pregnancy.[10][3][4]
Side effects
The most common side effects include headache, weakness, fatigue, upset stomach, constipation, and skin redness.[6] The overall profile of adverse effects is comparable to that of palonosetron (see Palonosetron#Adverse effects); no common adverse effects can be attributed to netupitant.[10]
Interactions
Pharmacology
History
Netupitant/palonosetron was approved for use in the United States in October 2014.[11] It was approved for use in the European Union in May 2015.[2] The intravenous version was approved in the United States in April 2018.[12][9]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "Netupitant/Palonosetron Monograph for Professionals". Drugs.com. Archived from the original on 28 January 2021. Retrieved 12 November 2021. Archived 28 January 2021 at the Wayback Machine
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 "Akynzeo EPAR". European Medicines Agency (EMA). 19 March 2020. Archived from the original on 19 March 2020. Retrieved 19 March 2020. Archived 19 March 2020 at the Wayback Machine
- ↑ 3.0 3.1 3.2 "Netupitant / palonosetron (Akynzeo) Use During Pregnancy". Drugs.com. 22 October 2018. Archived from the original on 19 December 2019. Retrieved 19 March 2020. Archived 19 December 2019 at the Wayback Machine
- ↑ 4.0 4.1 "Fosnetupitant / palonosetron (Akynzeo for Injection) Use During Pregnancy". Drugs.com. 22 October 2018. Archived from the original on 19 March 2020. Retrieved 19 March 2020. Archived 19 March 2020 at the Wayback Machine
- ↑ "Akynzeo 300 mg/0.5 mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). 11 February 2020. Archived from the original on 19 March 2020. Retrieved 19 March 2020. Archived 19 March 2020 at the Wayback Machine
- ↑ 6.0 6.1 6.2 "Akynzeo- netupitant and palonosetron capsule Akynzeo- fosnetupitant and palonosetron injection". DailyMed. 28 May 2020. Archived from the original on 18 October 2020. Retrieved 18 July 2020. Archived 18 October 2020 at the Wayback Machine
- ↑ 7.0 7.1 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 456. ISBN 978-0857114105.
- ↑ "Akynzeo Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 19 April 2021. Retrieved 12 November 2021. Archived 19 April 2021 at the Wayback Machine
- ↑ 9.0 9.1 "Drug Trials Snapshots: Akynzeo". U.S. Food and Drug Administration (FDA). 11 May 2018. Archived from the original on 24 January 2020. Retrieved 19 March 2020. Archived 24 January 2020 at the Wayback Machine
- ↑ 10.0 10.1 Haberfeld H, ed. (2015). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Akynzeo 300 mg / 0,5 mg Hartkapseln.
{{cite book}}
: CS1 maint: unrecognized language (link) - ↑ "Drug Approval Package: Akynzeo (Netupitant and Palonosetron) Capsules NDA #205718". U.S. Food and Drug Administration (FDA). 7 November 2014. Archived from the original on 19 March 2020. Retrieved 19 March 2020. Archived 19 March 2020 at the Wayback Machine
- ↑ "Drug Approval Package: Akynzeo (fosnetupitant and palonosetron) Injection". U.S. Food and Drug Administration (FDA). 31 May 2018. Archived from the original on 19 March 2020. Retrieved 19 March 2020. Archived 19 March 2020 at the Wayback Machine
External links
- AusPAR: Fosnetupitant (as chloride hydrochloride)/palonosetron (as hydrochloride). Therapeutic Goods Administration (TGA) (Report). October 2020. Archived from the original on 4 November 2020. Retrieved 2 March 2021.
- "Netupitant mixture with palonosetron". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 19 December 2019. Retrieved 2 March 2021. Archived 19 December 2019 at the Wayback Machine
- "Fosnetupitant". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 19 March 2020. Retrieved 2 March 2021. Archived 19 March 2020 at the Wayback Machine
- "Fosnetupitant and Palonosetron (Professional Patient Advice)". Drugs.com. Archived from the original on 23 October 2020. Retrieved 2 March 2021. Archived 23 October 2020 at the Wayback Machine
Identifiers: |
---|
- Pages using duplicate arguments in template calls
- Webarchive template wayback links
- CS1 maint: unrecognized language
- Use dmy dates from December 2019
- Articles with invalid date parameter in template
- Drugs with non-standard legal status
- Chemical articles with unknown parameter in Infobox drug
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drug has EMA link
- Articles containing unverified chemical infoboxes
- Drugs that are a combination of chemicals
- Articles with hatnote templates targeting a nonexistent page
- Antiemetics
- Combination drugs
- RTT